Published in Medical Letter on the CDC and FDA, November 30th, 2003
The company is working closely with the FDA to supply information and to finalize labeling.
"Seroquel is a treatment which has benefited millions of patients worldwide who suffer from schizophrenia, and we look forward to bringing this treatment option to the 2.3 million Americans who suffer from bipolar disorder," commented Don Beamish, Commercial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA